We consider the early stages of candidate development as being the most important ones. Most of the potential drugs are eliminated in toxicological and early clinical development and only a few manage to proceed to later stages.

Our services focus on this crucial phase. Analyzing the toxicological samples and providing scientific advice for a development strategy may be the start of our successful cooperation. Followed by Phase I-IIa investigations we accompany and support the crucial development phase. With our network of established partnerships we can even attend the complete research process.

There are many more reasons why we may be the perfect fit for you:

• Experience:
  The core team of SCOPE can look back on 20 years of experience in conducting early phase clinical trials.
• Consistency:
  It is a great challenge to prove consistency in such a dynamic market. We believe there is no better evidence as a team following the same vision since 1989.
• Flexibility:
  Our three different clinical units enable us to accomplish any type of Phase I-IIa trial — be it a First-In-Man or Bioequivalence study.
• Quality:
  We have an ambitious approach on quality management as well as quality control and successfully passed inspections by FDA, BfArM, and GLP authorities.
• Recruitment:
  As the second largest city in Germany, Hamburg provides perfect conditions for the recruitment of healthy volunteers and special patient populations.